Publications

Preclinical
Annals of Oncology
July 13, 2026
Re-evaluating antibody—drug conjugate linker stability: assessment, interpretation, and clinical translation
Colombo et al.
Preclinical
World Bispecific Summit
July 9, 2026
Optimizing Multispecific Antibody Design for Therapeutic Application
Dr. Paul Moore
Preclinical, ZW191
Clinical Cancer Research
July 1, 2026
ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile
Lawn et al.
Preclinical
T cell Engager Summit
June 24, 2026
Enhancing The Activity of T-Cell Engagers In Solid Tumors With CD28 Co-Stimulation​
Genevieve Desjardins, PhD
Clinical, ZW191
ESMO Gynaecological Cancers Congress
June 15, 2026
Efficacy analysis of ZW191 by folate receptor α (FRα) expression level in a phase 1 study
Hasegawa et al.
Preclinical, ZW1528
World Bispecific & T Cell Engager Summit
June 11, 2026
ZW1528, a Bispecific Antibody Targeting IL-4Ra and IL-33 Potently Inhibits Key Mediators of Airway Inflammation
Alexey Berezhnoy, PhD
Clinical, Zanidatamab
The New England Journal of Medicine
May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
Shitara et al.
Preclinical, ZW1528
Respiratory Innovation Summit
May 15 - May 16, 2026
ZW1528: IL-4Rα x IL-33 Bispecific Antibody for Treatment of COPD
Hardman et al.
Preclinical
PEGS
May 14, 2026
TriTCE Co-Stim: A Differentiated T Cell Engager Platform With Conditional Cis CD28 Co-Stimulation
Genevieve Desjardins, PhD
Preclinical
PEGS
May 12, 2026
Uniting Discovery Strategy and Engineering for the Best-in-Class Antibodies for ADCs
Righetto et al.
Clinical, ZW191
AACR
April 21, 2026
Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)–targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors: Part 1 dose-escalation results
LoRusso et al.
Preclinical
AACR
April 21, 2026
Unlocking novel biologies with bi- and trispecific antibodies: The importance of antibody format
Nina Weisser, PhD